Camrelizumab plus concurrent chemoradiotherapy for locally advanced cervical cancer: Preliminary results of a single-arm, open-label, phase II trial

被引：1
|
作者：
Xiao, Y. [1 ]
Cheng, H. [2 ,3 ]
Wang, L. [1 ]
Yang, L. [1 ]
Yu, X. [1 ]
机构：
[1] Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Dept Gynaecol Oncol, Zhengzhou, Peoples R China
[2] Zhengzhou Univ, Affiliated Canc Hosp, Dept Gynaecol Oncol, Zhengzhou, Peoples R China
[3] Henan Canc Hosp, Zhengzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.690
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
562P
引用
收藏
页码：S805 / S805
页数：1
相关论文
共 50 条
  • [41] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial.
    Wei, Wei
    Ban, Xiaohua
    Yang, Fan
    Huang, Yongwen
    Li, Jibin
    Qiu, Ya
    Cheng, Xiaqin
    Li, Jundong
    Zheng, Min
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial
    Gelderblom, Hans
    Cropet, Claire
    Chevreau, Christine
    Boyle, Richard
    Tattersall, Martin
    Stacchiotti, Silvia
    Italiano, Antoine
    Piperno-Neumann, Sophie
    Le Cesne, Axel
    Ferraresi, Virginia
    Penel, Nicolas
    Duffaud, Florence
    Cassier, Philippe
    Toulmonde, Maud
    Casali, Paolo
    Taieb, Sophie
    Guillemaut, Severine
    Metzger, Severine
    Perol, David
    Blay, Jean-Yves
    LANCET ONCOLOGY, 2018, 19 (05): : 639 - 648
  • [43] Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial
    Yamazaki, Tomoko
    Gunderson, Andrew J.
    Gilchrist, Miranda
    Whiteford, Mark
    Kiely, Maria X.
    Hayman, Amanda
    O'Brien, David
    Ahmad, Rehan
    Manchio, Jeffrey, V
    Fox, Nathaniel
    McCarty, Kayla
    Phillips, Michaela
    Brosnan, Evelyn
    Vaccaro, Gina
    Li, Rui
    Simon, Miklos
    Bernstein, Eric
    McCormick, Mary
    Yamasaki, Lena
    Wu, Yaping
    Drokin, Ashley
    Carnahan, Trevor
    To, Yy
    Redmond, William L.
    Lee, Brian
    Louie, Jeannie
    Hansen, Eric
    Solhjem, Matthew C.
    Cramer, Julie
    Urba, Walter J.
    Gough, Michael J.
    Crittenden, Marka R.
    Young, Kristina
    LANCET ONCOLOGY, 2022, 23 (09): : 1189 - 1200
  • [44] Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma (ImpactCRT): A single-arm, phase. trial
    Peng, Fang
    Bao, Yong
    Cheng, Chao
    Niu, Shaoqing
    Song, Wu
    Li, Yin
    Yu, Honglan
    Xing, Xiangbin
    Feng, Shiting
    Wang, Xiaoyan
    Lian, Huimin
    Yu, Tiantian
    Wu, Jialiang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
    Cao, Yanshuo
    Lu, Ming
    Sun, Yu
    Gong, Jifang
    Li, Jie
    Lu, Zhihao
    Li, Jian
    Zhang, Xiaotian
    Li, Yan
    Peng, Zhi
    Zhou, Jun
    Wang, Xicheng
    Shen, Lin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (02) : 779 - 789
  • [46] Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
    Yanshuo Cao
    Ming Lu
    Yu Sun
    Jifang Gong
    Jie Li
    Zhihao Lu
    Jian Li
    Xiaotian Zhang
    Yan Li
    Zhi Peng
    Jun Zhou
    Xicheng Wang
    Lin Shen
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 779 - 789
  • [47] Neoadjuvant tislelizumab plus chemotherapy among patients with locally advanced cervical cancer: A prospective, single-arm, phase II trial
    Sheng, Jindong
    Liu, Wenxin
    Liu, Ruoyan
    Liu, Chunyan
    Wang, Bochang
    Liu, Xiangyu
    Xu, Changxiao
    Fu, Xin
    Wang, Ke
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S14 - S14
  • [48] A prospective, single-arm, open-label, phase II clinical trial on efficacy and safety of cadonilimab plus anlotinib for recurrent, metastatic or persistent cervical cancer
    Yang, Chunxu
    Sun, Shaoxing
    Xiang, Qingming
    Chen, Min
    Mei, Zijie
    Wu, Qiuji
    Qiu, Hui
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S290 - S290
  • [49] Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Non-Squamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
    Ren, S.
    He, J.
    Fang, Y.
    Chen, G.
    Ma, Z.
    Chen, J.
    Guo, R.
    Lin, X.
    Yao, Y.
    Wu, G.
    Wang, Q.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S924 - S924
  • [50] Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial
    Kroiss, Matthias
    Quinkler, Marcus
    Johanssen, Sarah
    van Erp, Nielka P.
    Lankheet, Nienke
    Poellinger, Alexander
    Laubner, Katharina
    Strasburger, Christian J.
    Hahner, Stefanie
    Mueller, Hans-Helge
    Allolio, Bruno
    Fassnacht, Martin
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (10): : 3495 - 3503
12345